If you are asking, “am I eligible for Mounjaro?”, the answer is rarely based on weight alone. Mounjaro is a prescription-only medicine, and a clinician needs to look at your BMI, medical history, current medicines and weight-management goals before deciding whether it is appropriate. That review is there to keep treatment safe, useful and tailored to you – not to create unnecessary barriers.
For many people who have tried to lose weight through food choices and activity but found that results do not last, clinically supported treatment can offer a different route forward. It still requires commitment, but it should not require appointments that are difficult to fit around work, family or everyday life.
Am I eligible for Mounjaro in the UK?
Mounjaro contains tirzepatide. It is licensed in the UK for weight management alongside a reduced-calorie diet and increased physical activity. It is also used in the treatment of type 2 diabetes, though the treatment pathway and clinical considerations may differ.
For weight management, clinicians will commonly consider Mounjaro for adults with a BMI of 30 kg/m² or above. You may also be considered if your BMI is 27 kg/m² or above and you have at least one weight-related health condition. These can include high blood pressure, abnormal blood fats, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes.
BMI is a useful starting point, not a complete picture of health. A clinician may also consider your waist measurement, previous weight-loss attempts, relevant medical conditions and the medicines you take. For people from some ethnic backgrounds, health risks linked to excess weight can occur at a lower BMI, so an individual assessment matters.
Eligibility through a private pharmacy service is not the same as eligibility for NHS treatment. NHS availability can depend on local services, phased rollout criteria and specific clinical thresholds. A private prescription is still subject to a full clinician review and the same need for safe prescribing.
What BMI means in practice
BMI compares weight with height. It does not measure body composition or explain every health risk, but it helps clinicians apply the medicine’s licensed criteria consistently. During an online consultation, you will normally be asked for your height and current weight, as well as information that helps verify your eligibility.
Being close to a BMI threshold does not guarantee or rule out treatment on its own. The clinician’s responsibility is to decide whether the expected benefits outweigh the possible risks for you.
When Mounjaro may not be suitable
A prescription is never automatic, even if you meet the BMI criteria. Mounjaro may not be appropriate if you are pregnant, trying to conceive, breastfeeding, or have had a serious allergic reaction to tirzepatide or any of the treatment’s ingredients.
You should tell the clinician if you have a history of pancreatitis, severe stomach or bowel problems, gallbladder disease, diabetic retinopathy, kidney problems or liver problems. These do not always mean treatment is impossible, but they may affect whether Mounjaro is suitable or how closely you should be monitored.
It is also important to disclose a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2. Although animal studies raised concerns about thyroid tumours, the relevance to people is not known. Your clinician will consider this history carefully when assessing treatment.
Mounjaro should not be used alongside another GLP-1 receptor agonist, such as Wegovy, Ozempic, Saxenda or Rybelsus, unless a specialist has explicitly advised otherwise. Taking overlapping medicines from the same treatment family does not improve results and can increase the chance of side effects.
Your medicines matter as much as your BMI
Tirzepatide slows stomach emptying, particularly when treatment starts and when the dose is increased. This can affect how quickly some oral medicines are absorbed. Make sure you include every prescription medicine, over-the-counter product and supplement in your consultation.
If you take insulin or a sulphonylurea for diabetes, your prescriber may need to adjust your treatment because the risk of low blood sugar can increase. Mounjaro is not a substitute for careful diabetes management, and you should not change a diabetes medicine without clinical advice.
People using oral contraception need specific guidance. Mounjaro may reduce the effectiveness of the contraceptive pill when you start treatment and for four weeks after each dose increase. A clinician may advise using a barrier method as well, or choosing a non-oral contraceptive option during these periods.
This is why a proper assessment asks more than a few questions about your weight. Safe prescribing depends on the whole clinical picture.
What happens during an online Mounjaro assessment?
A well-designed consultation should be clear and personal. You will usually provide your height, weight, health conditions, current medicines, allergies and relevant treatment history. You may also be asked about pregnancy plans, your relationship with food, and what support you have tried previously.
A UK-based prescriber then reviews your information. They may approve treatment, recommend a different option, ask for further details or advise that Mounjaro is not right for you at this time. That is a clinical decision, not a chatbot response.
If approved, treatment normally begins at a low weekly dose. The dose is increased gradually, where appropriate, to help your body adjust and to balance effectiveness with tolerability. Online UK Pharmacy provides clinician-reviewed treatment, direct dispensing and discreet plain-packaged delivery, with continuity of care available as you progress.
Eligibility is also about readiness for treatment
Mounjaro can reduce appetite and help many people lose clinically meaningful weight, but it is not a quick fix or a replacement for eating well. It works best when you have a realistic plan for meals, protein intake, fluids, movement and managing social occasions.
Common side effects can include nausea, diarrhoea, constipation, vomiting, stomach discomfort and reduced appetite. They are often most noticeable after starting or increasing a dose, and may settle with time. Smaller meals, avoiding very rich foods and staying hydrated can help, but persistent or severe symptoms should be discussed with your clinical team.
Seek urgent medical advice for severe and persistent abdominal pain, especially if it is accompanied by vomiting, as this could indicate pancreatitis. You should also get help promptly if you develop signs of a serious allergic reaction, such as swelling of the face or throat, difficulty breathing, or a widespread rash.
Weight regain can happen when treatment stops, particularly if the habits that support weight maintenance are not in place. For that reason, it helps to view Mounjaro as part of a longer-term weight-management plan rather than a short course with a finish line.
A clinician can give you a clear answer
You do not need to have every detail of your health perfectly organised before seeking support. You do need to answer the consultation honestly, including anything that feels sensitive or unrelated. Those details allow the prescriber to make a safer decision and suggest the right next step.
If Mounjaro is suitable, you can begin with a clear treatment plan and ongoing clinical support. If it is not, a thoughtful assessment can still move you towards an option that better fits your health, your circumstances and the results you want to sustain.
